Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hybrid stroke unit aims to cut lifesaving treatment time

NCT ID NCT07670065

Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a new emergency stroke unit, equipped with a hybrid CT and X-ray machine (NeuAngio-CT), can speed up clot removal in people having a severe stroke. About 232 adults aged 18-60 with acute ischemic stroke will be randomly assigned to either the new approach or standard care. The main goal is to see if the new unit reduces the time from the start of the procedure to restoring blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hybrid CT/DSA emergency stroke unit (NeuAngio-CT) for guiding thrombectomy
What this could lead to
If successful, this approach could significantly reduce the time to restore blood flow in stroke patients, potentially improving recovery and reducing disability.
What could go wrong
This is a single-center trial with 232 participants, so results may not apply broadly. The new device may not speed up treatment as hoped, and there are risks from the procedure itself, such as bleeding or vessel damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age 18-60 years; 2. Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment; 3. Time from symptom onset or last known well ≤ 24 hours; 4. Intravenous intracranial and cervical CT angiography completed; 5. Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings; 6. Written informed consent obtained from the patient or their legally authorized representative. Exclusion Criteria 1. Known contrast agent allergy; 2. Renal insufficiency with GFR (glomerular filtration rate) \< 45 mL/min/1.73 m²; 3. History of kidney transplantation; 4. Concomitant diabetes mellitus with current use of metformin; 5. Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission; 6. Refractory hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy); 7. Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging; 8. Any other serious comorbidity or complication that may interfere with study conduct or evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke Large vessel occlusion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tiantan Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.